Helius Therapeutics is set to release drugs containing THC soon, all grown and manufactured in New Zealand.
Earlier, the country's largest licensed medicinal marijuana company was awarded a Good Manufacturing Practice (GMP) certificate from MedSafe, allowing them to produce THC medication.
2022 is a pivotal year for Helius. Achieving these milestones will enable us to bring more New Zealand-grown and manufactured products to patients in New Zealand," said Carmen Doran, CEO of Helius Therapeutics.
Last week, we announced our GACP certification. Now, we have achieved GMP certification in an additional four processes at our spacious East Auckland factory. This progress demonstrates the team collaboration culture being established at Helius," she said.
In July 2021, Helius obtained their first GMP certification and pharmaceutical manufacturing license. Since then, they have become the first company in New Zealand to launch and offer products made and grown in New Zealand. They are now the first company in New Zealand to obtain GMP certification for THC drugs.
In 2018, Helius began a rigorous and complex journey to achieve GMP certification as a startup. With international recognition and the latest approval from MedSafe meeting European standards, known as EU-GMP, this 100% New Zealand company now has potential for future export opportunities.
The GMP certification process is very thorough, and rightfully so. As we are in the business of pharmaceuticals, we cannot afford to cut corners. Helius has assembled a team of leaders with international experience in both the pharmaceutical and medicinal cannabis industries, and we have successfully achieved this level of compliance," she said.
As a leader in New Zealand's newest industry, Helius has been working with regulatory bodies from the beginning to ensure patient safety.
Carmen Doran, CEO of Helius, has been appointed to the New Zealand Medical Cannabis Council. This organization seeks to support the local industry and provide high-quality export products for patients worldwide. Doran stated that Helius has established teams and facilities to improve patients' quality of life and is dedicated to this goal.
Helius is utilizing vertical integration from the factory to the patient. Its operations link variety breeding with yield optimization, precise extraction of high-value cannabinoids, next-generation drug development, GMP production, and academic and scientific partnerships.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
